APA (7th ed.) Citation

Abdollahi, A., Favata, M., Weber, M., Roman, V., Hess, R., Hammond, K., . . . Amador-Arjona, A. The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Abdollahi, Angela, et al. The FGFR Inhibitor Pemigatinib Overcomes Cancer Drug Resistance to KRAS G12C Inhibitors in Mesenchymal Lung Cancer. Public Library of Science (PLoS).

MLA (9th ed.) Citation

Abdollahi, Angela, et al. The FGFR Inhibitor Pemigatinib Overcomes Cancer Drug Resistance to KRAS G12C Inhibitors in Mesenchymal Lung Cancer. Public Library of Science (PLoS).

Warning: These citations may not always be 100% accurate.